Emisphere Technologies, Inc. (Tarrytown, NY, www.emisphere.com) has signed a multi-product research agreement with Roche (Basel, Switzerland, www.roche.com) to explore the use of Emisphere's eligen technology in feasibility studies for new oral formulations of Roche molecules.
The nanotechnology vision of tiny microrobots that could move inside the body carrying out complex surgical repairs has been touted incessantly until it has become a clich?.
Ray (Rui) Zhong has joined China Biopharmaceuticals Holdings, Inc. (CHBP)?(Beijing, China, www.cbioinc.com) as senior vice president, finance and business development.
Mark Goldberger has been named the first medical director for Emerging and Pandemic Threat Preparedness at the Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration.
Plast-O-Matic Valves (Cedar Grove, NJ, www.plastomatic.com) offers a low-cost flow control valve in natural polypropylene, PVC, and other rugged thermoplastics to maintain a constant, pre-determined flow in a piping system.
Biotechnology and pharmaceutical companies seeking to train employees, or even to create their own "online university" can now partner with The Pharmaceutical Institute (PI, Raleigh, NC, www.pharmainstitute.com).
Envita Natural Centers of America (Scottsdale, AZ, www.behealthyamerica.com) received a warning letter from the FDA on June 14 that states that the firm's manufacturing process violates the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act.
Poniard Pharmaceuticals, Inc. (Seattle, WA, www.poniard.com) has appointed Alan B. Glassberg, MD, as its chief medical officer.
Biocon Ltd. (Bangalore, India, www.biocon.com) has signed a licensing agreement with Bayer Healthcare LLC (www.bayerhealth.com), a subsidiary of Bayer AG (Leverkusen, Germany) for exclusive rights for its branded recombinant human insulin, Insugen, in China.
Catherine Wachira has joined The US Pharmacopeia (USP, www.usp.org), as director of the Drug Quality and Information (DQI) program.
Buffett prefers to buy small, publicly traded companies with ample room for growth.
Northfield Laboratories Inc. (Evanston, IL, www.northfieldlabs.com) has agreed to purchase a building it previously leased in Mt. Prospect, IL, to house its first commercial manufacturing facility to produce PolyHeme, Northfield?s human hemoglobin-based oxygen carrier, used to treat urgent, large-volume blood loss in trauma and surgical settings.
BioFlo 310 Benchtop Fermentor; Chromatography Sorbents for Protein Purification
The Naval Health Research Center (NHRC); Nastech Pharmaceutical Company Inc.; Amylin Pharmaceuticals, Inc.; Metabolex Inc.; Ortho-McNeil Inc.
Schering-Plough (Kenilworth, NJ, www.sch-plough.com) will establish Schering-Plough Produtos Farmaceuticos Limitada in Sao Paulo, Brazil, to market its core products.
GTC Biotherapeutics Inc. (Framingham, MA, www.gtc-bio.com) has been awarded a $1 million payment from LEO Pharma A/S (Ballerup, Denmark, www.leo-pharma.dk) for receiving a positive opinion on a market authorization application for ATryn, from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency (EMEA).
Wayne T. Smith; Steven Niedelman; Diana Kolaitis; David Horowitz; Deborah M. Autor; Florence Houn, MD; Julie Beitz, MD
A symposium at the AAPS National Biotechnology Conference in Boston, June 19-22, 2006, addressed key concerns and new developments in manufacturing biologic products in a sterile environment.
"Clinical data is the gold standard" for setting manufacturing specifications, said Patrick Swann, PhD, acting deputy director of the Division of Monoclonal Antibodies at FDA, at a session on specification setting at the AAPS National Biotechnology Conference that was held June 19-21 in Boston.
Protein aggregation is a term that can include many types of aggregation, from rapidly reversible aggregation caused by non-covalent bonds to irreversible aggregation in the form of covalent oligomers.
On August 12, 2003, Johnson & Johnson began recalling certain batches of its anemia drug, Eprex (epoetin alfa, sold as Procrit in the US), in most countries outside of the United States.
Several recent approvals highlight progress in developing both prophylactic and therapeutic vaccines.
In the biotech industry, everyone wants to get to market fast. But what if you have to build a manufacturing facility first? At Interphex 2006, Roger Lias, PhD, vice-president of sales and business development at Cytovance Biologics (Oklahoma City, OK, www.cytovance.com), explained how his company did it quickly. In August of this year, the company expects to complete validation of a new cGMP contract manufacturing facility for biopharmaceuticals derived from mammalian cell culture ? just 25 months after the original groundbreaking.
Data from recent Biotech/Pharmaceutical Industry Conference/Events
Instead of investing in new facilities, the industry should focus on improving manufacturing technology to increase yields, says Timothy Charlebois, PhD, director of cell and molecular sciences for Wyeth (Madison, NJ, www.wyeth.com). Charlebois made these remarks in his introduction to the session, "Frontiers and Economics of Mammalian Cell Expression," at the BIO 2006 convention."I've seen examples where we took a process that produced 3 grams of protein per liter, and were able to optimize it so that it produced 9.6 g/L," he said, adding that future yields are likely to be above 10 g/L.
2 JANUARY - FDA has issued guidance for the blood industry regarding procedures for properly qualifying potential blood donors who have recently been inoculated with the smallpox vaccine (vaccinia virus) or those who may have had other direct exposure to smallpox vaccines.
25 OCTOBER - This guidance document provides our recommendations for assessing donor suitability and product safety for donors with proven West Nile Virus (WNV) infections or with illnesses potentially due to WNV. This guidance applies to Whole Blood and blood components intended for transfusion and blood components including recovered plasma, Source Leukocytes and Source Plasma intended for use in further manufacturing into injectable products or non-injectable products.
14 OCTOBER - German scientists believe they can almost instantly screen blood for the agent that causes the human form of mad cow disease, an achievement that could root out the risk of spreading the disorder by blood donation.
24 SEPTEMBER - CDER has released a list of guidances they plan to develop.
24 SEPTEMBER - Biotechnology Industry Organization (BIO) President Carl B. Feldbaum today issued the following statement regarding White House intentions to nominate Mark B. McClellan, M.D., Ph.D., for commissioner of the Food and Drug Administration, according to newspaper reports:
